Defining antibodies by functional features is not always straightforward at the EPO. T326/22 is a nice example of how this can be achieved.
To briefly recap the standard EPO approach, an…
On 9 January 2025 I reported on Parts 1 and 2 of a three-part article in EPI Information by Tamaris Bucher, a Principal Patent Attorney at Novartis Pharma AG, on the current approach to antibody…
The festive period normally leads to a slight slow-down in work in Europe and as such, it can provide the opportunity to catch up on wider reading as well as to grab a little rest. In between the…
On December 23, the Brussels Enterprises Court issued a significant judgment confirming that Samsung Bioepis' notification complies with the legal requirements for relying on the SPC Manufacturing…
Although plastics are essential to the economy, plastic pollution is threatening ecosystems all over the planet. Plastic waste remains in the environment, taking from decades to centuries to…
On 8 October 2024, Mr Justice Meade handed down judgment in BioNTech SE and Pfizer Inc., (together, BioNTech/Pfizer) v CureVac SE. Meade J found CureVac's patents, relating to split poly(A) tails in…
Reading the title of this paper, perhaps you will smile, thinking about all the discussions that this issue has already ignited, even before the UPC came into force. Since the beginning, most…
Moderna secured a double victory in the Patents Court last week (2 July 2024) in proceedings against Pfizer and BioNTech. In the first decision, Meade J found its modified mRNA patent to be valid…
Prepared by Rob Rodrigues, Brenno Telles and Dara Offrede
On Friday June 21, 2024, the government formally introduced regulations addressing the new framework for Partnerships for Productive…
